Lu177-PSMA: A Smart Bomb Against Prostate Cancer
Lu-177 PSMA Targeted Radioligand Therapy is an innovative molecular therapy designed for patients with advanced metastatic castration-resistant prostate cancer (mCRPC). Most prostate cancer cells overexpress a protein called PSMA (Prostate-Specific Membrane Antigen) on their surface. The radioactive isotope Lutetium-177 used in this therapy can precisely target and attach to cancer cells. It delivers localized beta (β) radiation directly into the cells, destroying tumors from within while minimizing damage to surrounding healthy tissues. Clinical studies show that this therapy can effectively reduce tumor size, lower PSA (prostate-specific antigen) levels, and extend patient survival. Common side effects, such as dry mouth or fatigue, are usually manageable and temporary.
Please seek professional medical advice from your referring doctor for associated risks and efficacy. Generally, a range of screening tests including a PSMA PET-CT scan are required for thorough diagnosis and assessment before undergoing this therapy.
- For more information about our screening PET scan service, please refer to another article.
- For appointments or inquiries, please contact us at hotline 27148263 / email to booking@sthscan.com / WhatsApp us.